Molecular Mechanism of Avicennia Marina in Inhibiting Hepatitis C Virus Based on Network Pharmacology and Molecular Docking
April 2025
in “
Tropical Journal of Natural Product Research
”
Studysummary In this study, researchers using network pharmacology and molecular docking methods found that compounds from Avicennia Marina could inhibit hepatitis C virus infection by targeting key proteins such as AKT1 and TNF-α, showing potential for anti-HCV treatments.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This study investigates the potential of Avicennia marina (AM) to inhibit Hepatitis C virus (HCV) infection using network pharmacology and molecular docking. It identifies 12 compounds and 11 core targets, with 5 key targets (SRC, AKT1, TNF, HSP90AA1, and ESR1) meeting specific criteria. Molecular docking shows that several AM compounds have lower binding energy than native ligands, indicating strong inhibitory potential. Notably, Avicennone D effectively inhibits AKT1 and TNF-α, while Avicenol C and Avicennone F show strong potential against TNF-α and HSP90AA1. The study highlights AM's potential in treating HCV by targeting key proteins.
